PPA
PCVX icon

Parametric Portfolio Associates’s Vaxcyte PCVX Stock Holding History

Parametric Portfolio Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,565
Closed -$228K – 3744
2021
Q4 		$228K Sell
9,565
-2,976
-24% -$69.2K ﹤0.01% 3378
2021
Q3 		$318K Sell
12,541
-13,437
-52% -$326K ﹤0.01% 3277
2021
Q2 		$585K Buy
+25,978
New +$532K ﹤0.01% 3017
2021
Q1 		– Sell
-35,663
Closed -$948K – 4077
2020
Q4 		$948K Buy
35,663
+16,769
+89% +$623K ﹤0.01% 3078
2020
Q3 		$933K Buy
+18,894
New +$752K ﹤0.01% 2965

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Parametric Portfolio Associates's PCVX Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Vaxcyte (PCVX) in Q1 2022, closing a stake of 9,565 shares — an estimated $228K sold.

Parametric Portfolio Associates first reported a position in PCVX in Q3 2020 and held it in 5 quarters. The position peaked at $948K in Q4 2020. 88 funds tracked by Wall St. Rank hold PCVX as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Vaxcyte position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 9,565 Vaxcyte shares in Q1 2022, an estimated $228K.
  • Parametric Portfolio Associates first reported a position in Vaxcyte in Q3 2020 and held it in 5 quarters.
  • Parametric Portfolio Associates's Vaxcyte position peaked at $948K in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.